Company intelligence
K36 Therapeutics, Inc.
Translating epigenetic modulation of oncogenic pathways NSD2 / MMSET into first-in-class small molecule therapeutics.
Biotechnology Research
Cambridge, US
11–50 employees
Founded 2021
4 public signals
About K36 Therapeutics, Inc.
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics.
Verified activity
Signals from K36 Therapeutics, Inc.
4 published signals
Research & Knowledge
K36 Therapeutics, Inc. is exploring the potential of targeting NSD2 in multiple myeloma with clinical program KTX-1001, which is a clinical trial for gintemetostat.
Reported by K36 Therapeutics, Inc.
Research & Knowledge
K36 Therapeutics, Inc. is exploring the potential of targeting NSD2 in metastatic castration-resistant prostate cancer with clinical program KTX-2001, which is a clinical trial for a drug.
Reported by K36 Therapeutics, Inc.
Research & Knowledge
K36 Therapeutics, Inc. is advancing research for men with metastatic castration-resistant prostate cancer through STRIKE-001, a Phase 1 clinical trial evaluating KTX-2001, an investigational oral NSD2 inhibitor.
Reported by K36 Therapeutics, Inc.